Open Access

An unusual cause of fatal rapid-onset ataxia plus syndrome

Cerebellum & Ataxias20174:5

DOI: 10.1186/s40673-017-0063-9

Received: 6 November 2016

Accepted: 4 April 2017

Published: 21 April 2017

Abstract

Background

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disorder of the central nervous system caused by reactivation of the JC-virus and is in most cases associated with underlying immunosuppression. Acquired immune deficiency syndrome (AIDS) and hematological malignancies are well-known predisposing factors for PML. However, in the past ten years, various pharmacological agents have been associated with increased risk of PML. Based on the phenomenology PML can be divided into the cerebral form and the rare cerebellar form.

Case presentation

Here we describe a man affected by polycythemia vera (PCV) that was treated with hydroxyurea (HU) and developed PML. The initially PML presentation included ataxia as one of the main features. Brain MRI displayed widespread supratentorial and infratentorial lesions. Immunological analysis revealed absence of reactivity to a wide range of antigens. The course of disease was rapidly progressive with fatal outcome - autopsy ruled out leukemic transformation.

Conclusion

The occurrence of PML in PCV patients is very rare and has been reported only once. Movement disorders, such as ataxia, are also less frequent. In the present case the PML was likely multifactorial.

Keywords

PML Ataxia JC-virus Polycythemia vera Hydroxyurea FASCIA analysis

Background

The association between polycythemia vera (PCV) and progressive multifocal leukoencephalopathy (PML) is very rare and has been reported only once [1]. This previously reported patient with PCV was treated with interferon (IFN)-α2B and thalidomide, but not hydroxyurea. In most cases PML is associated with immunodeficiency [2, 3]; however in very rare occasions it may also afflict immunocompetent patients [4]. The most frequent symptoms are motor weakness, changes in mentation and impaired vision [5], whereas movement disorders are less frequently seen [6].

Case presentation

An 81 year-old man presented with subacute disorientation, mild left-side weakness, impaired balance, apraxia and unilateral spatial neglect in May 2015. His past medical history included arterial hypertension and a stable course of PCV, diagnosed at the age of 66, treated with hydroxyurea (HU), low dose acetylsalicylic acid (ASA) and occasional phlebotomy. Upon admission in May 2015 a brain CT scan revealed a hypodense area in the right temporal lobe initially interpreted as a subacute infarction. Mild anemia was found and HU was discontinued. The patient was referred to a rehabilitation clinic, but his condition deteriorated rapidly in the following days. On readmission left-side weakness, marked contralateral limb ataxia, dysdiadochokinesia, bradykinesia, dysarthria, left homonymous hemianopia and left-sided hemianesthesia were evident. Brain MRI performed at this point displayed multifocal and punctate slightly expansive white matter non-contrast enhanced juxta- and subcortical lesions, predominantly in the right hemisphere. These lesions were more confluent around the right trigonum and within the right temporal lobe and brainstem. There was involvement of the right cerebral peduncle, anterior pons on the right side, right middle cerebellar peduncle and the cerebellum around the dentate nucleus. On diffusion-weighted imaging (DWI) lesions were hyperintense but without restricted diffusion as the apparent diffusion coefficients (ADC) were not decreased in the area (Fig. 1). EEG-recording revealed non-epileptiform abnormalities such as slow wave activities over right hemisphere and maximum over right temporal region.
Fig. 1

Brain MRI displaying PML features in a PCV patient treated with hydroxyurea. Axial and coronal T1-weighted sections displaying multifocal and confluent supra- and infratentorial lesions without contrast enhancement (arrows). There are also supratentorial punctate lesions (indicated by an arrow head). To the right T2-weigthed section displaying lesions in the right cerebellar hemisphere (arrow). No restricted diffusion

A lumbar puncture was performed and yielded normal cell count and protein content in the cerebrospinal fluid (CSF). Enterovirus, herpes simplex 1 and 2, varicella zoster and CMV, were ruled out in the CSF by means of PCR and ELISA analysis. Serology for Lyme’s disease and syphilis in the CSF was also negative. Onconeural antibodies were not detected in blood. A centrifugated CSF sample was analyzed with fluorescence-activated cell sorting (FACS) which identified only few T-cells. Neurofilament light protein (NfL) was markedly elevated (16500 ng/L; reference interval <1850). Analysis for JC-virus yielded 7 400 copies/mL and tests for BK-virus, HIV, and HTLV-1 tests were negative. A second MRI of the brain three weeks after admission displayed an increased number of widespread supra- and infratentorial lesions (Fig. 2). Additional laboratory investigation at this point revealed mild lymphopenia with decreased amounts of all lymphocyte fractions but not NK-cells. A flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA) analysis revealed poor response to mitogens and specific antigens as shown in table (Table 1).
Fig. 2

Brain MRI on day 38 of admission in a male with underlying PCV who developed PML. Axial T2-weighted sections display increased number of widespread and confluent supra- and infratentorial lesions. There were several “ring-shaped” lesions with hyperintensive periphery on DWI, increased central signal and isointense periphery on ADC. On T2-weighted images the lesions were globally hyperintense

Table 1

FASCIA analysis

Analysis

Results

Reference interval

CD 4 PWM

106

233 – 2189 c/μL

CD 8 PWM

5

50 – 549 c/μL

CD 19 PWM

17

42 – 741 c/μL

CD 4 ConA

113

620 – 3800 c/μL

CD 8 ConA

1

180 – 1757 c/μL

CD 4 Influenza

0

19 – 1050 c/μL

CD 4 PPD

0

11 – 2022 c/μL

CD 4 Candida

0

51 – 1014 c/μL

Flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA-analysis) revealed response absence of reactivity to a wide range of antigens. Response to lectins (pokeweed mitogen and concanavalin A) was moderately mitigated, whereas response to influenza antigen, purified protein derivative antigens and Candida antigen was completely absent

Different therapeutic options for PML were considered [7], but due to the rapid clinical deterioration treatment was withheld. The patient developed manifest left-sided hemiplegia, horizontal nystagmus, and verbal unresponsiveness. At this point his condition had worsened and the subject became unable to swallow, he contracted recurrent pneumonias and required a percutaneous endoscopic gastrostomy. During the later course of disease he remained in an unresponsive state until he died of pneumonia. Total disease duration in this case was two months. Post mortem studies of the bone marrow demonstrated a picture consistent with PCV but no signs of leukemic transformation. Histopathological analysis of the brain confirmed progressive multifocal leukoencephalopathy (PML) (Fig. 3).
Fig. 3

Histopathological findings. On coronal sections of the brain the white matter of the right temporal and frontal lobes was soft and its color grey-pink. Similar changes were also seen in the right cerebellar hemisphere (arrow head). On microscopy, widespread white matter lesions in those regions with destruction of myelin and the presence of large astrocytes and enlarged oligodendrocytes were evident. Some astrocytes had a bizarre appearance (arrow on picture below). Many similarly small white matter lesions were also present in the left cerebral hemisphere and the brainstem

Discussion and Conclusions

PML is often a fatal disease as in this described case. It can be divided into the cerebral form which is more common and the cerebellar from. The latter can also affect the brainstem [8, 9]. Infratentorial PML is rare, and so far there are only 30 case reports of infratentorial PML in the PubMed database [10]. In the presented case the initial symptom was hemiplegia, but only within a few days a focal movement disorder, i.e. limb ataxia, became one of the main features of the patient’s condition.

Very few sporadic cases of PML have been described and reported in individuals without obvious immunosuppression or immunosuppressive risk factors [6, 8]. The vast majority of PML infections affect immunosuppressed patients. A CD4 count below 200 cells/μL has been identified as a major risk factor for PML in deeply immunosuppressed patients with AIDS [11]. On the other hand, deleterious effects of hydroxyurea on CD4 lymphocytes have been described in children [12], but not in adults. In addition, myeloid malignancy such as PCV is not perceived as an immunosuppressive state. However, the natural process of immunological senescence involves both quantitative shifts and decreased functional capacity of various lymphocyte population subsets. Poor response of lymphocytes to mitogens can be seen in patients with immunological dysfunction or in patients with immunosuppressive treatments. The FASCIA results described here should therefore be interpreted in the context of a mild lymphopenia. In the described case, old age, myeloid malignancy and chemotherapy were likely the three factors that could have potentially contributed to JC-virus reactivation and development of a fatal disease. It is however difficult to pinpoint a single cause of PML in this case. Nevertheless, awareness of the potential consequences of such a constellation is important. PML should be considered as a differential diagnosis, especially in a PCV patient with rapidly progressive neurological symptoms without obvious immunosuppression or leukemic transformation.

Abbreviations

AIDS: 

Acquired immune deficiency syndrome

CNS: 

Central nervous system

CSF: 

Cerebrospinal fluid

FASCIA: 

Flow-cytometric assay of specific cell-mediated immune response in activated whole blood

HU: 

Hydroxyurea

JCV: 

John Cunningham virus

PCV: 

Polycythemia vera

PML: 

Progressive multifocal leukoencephalopathy

Declarations

Acknowledgments

We express our gratitude to the patient’s widow for consenting to this report. Thanks to Dr. I. Schliemann at the Department of Pathology. Martin Paucar was supported by the Stockholm County Council.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

Dr. IK and Dr. MP: data collection and writing of the manuscript. Dr. IN and Dr. MK: pathological studies and editing of the manuscript. Dr. FH and Dr. EK: MRI imaging analysis and editing of the manuscript. Dr. DH and Dr. JW: editing of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written consent from the next of kin was obtained and can be sent upon request.

Ethics approval and consent to participate

Since this is a single case report we did not consider applying to the ethics committee in Stockholm. We have discussed this issue in similar situations at our department and decided to obtain consent from the patient or the closest relative. This is what we did. The widow was informed of our intentions (we talked to her and sent written information) and she signed consent for publication since the patient wasn’t able to consent.

We don’t have an ethical committee at our hospital. The ethical committee is regional and it covers mostly studies (pharmacological, observational, interventions, etc.). An application has a cost (5–16 000 SEK) and is not practical to perform for case reports.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurology, Karolinska University Hospital
(2)
Department of Clinical Immunology, Karolinska University Hospital
(3)
Department of Radiology, Karolinska University Hospital
(4)
Department of Clinical Pathology and Cytology, Karolinska University Hospital
(5)
Department of Clinical Neuroscience, Karolinska Institute

References

  1. Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196(5):709–11.View ArticlePubMedGoogle Scholar
  2. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430–8.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–39.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010;81(3):247–54.View ArticlePubMedGoogle Scholar
  5. Berger JR. The clinical features of PML. Cleve Clin J Med. 2011;78 Suppl 2:S8–12.View ArticlePubMedGoogle Scholar
  6. Stockhammer G, Poewe W, Wissel J, Kiechl U, Maier H, Felber S. Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder. Mov Disord. 2000;15(5):1006–9.View ArticlePubMedGoogle Scholar
  7. Kalisch A, Wilhelm M, Erbguth F, et al. Progressive multifocal leukoencephalopathy in patients with a hematological malignancy: review of therapeutic options. Chemotherapy. 2014;60(1):47–53.View ArticlePubMedGoogle Scholar
  8. Arai Y, Tsutsui Y, Nagashima K, Shinmura Y, Kosugi T, Wakai M, Nishikage H, Yamamoto J. Autopsy case of the cerebellar form of progressive multifocal leukoencephalopathy without immunodeficiency. Neuropathology. 2002;22(1):48–56.View ArticlePubMedGoogle Scholar
  9. Parr J, Horoupian DS, Winkelman AC. Cerebellar form of progressive multifocal leukoencephalopathy (PML). Can J Neurol Sci. 1979;6(2):123–8.View ArticlePubMedGoogle Scholar
  10. Fukami S, Akimoto J, Ichikawa M, Jimbo H, Ikeda Y, Ishimura Y, Nanri K, Tsuchiya K, Kohno M. Primary cerebellar progressive multifocal leukoencephalopathy (PML) shows increased accumulation in (123)I-IMP SPECT. J Neurol Sci. 2016;361:92–4.View ArticlePubMedGoogle Scholar
  11. Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12:1149–54.View ArticlePubMedGoogle Scholar
  12. Lederman HM, Connolly MA, Kalpatthi R, et al. Immunologic Effects of Hydroxyurea in Sickle Cell Anemia. Pediatrics. 2014;134(4):686–95.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement